Hydrogen Research Study
← Back to Research Library
Human clinical evidenceHuman Clinical Studyhydrogen-rich water

Hydrogen-rich water alleviates inflammation and fatigue in COVID-19: A pilot study

Aleksandra Milovancev, Jovana Avakumovic, Patrik Drid, Nikola Todorovic, Valdemar Stajer, Sergej M Ostojic · European Journal of Inflammation · 2022

Research-use notice

Independent study record

Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.

H2HUBB Research Library branded molecular hydrogen research image
Primary topic Respiratory and Lung Health
Evidence type Human clinical evidence
Publication type Human Clinical Study
Hydrogen method hydrogen-rich water

H2HUBB TAKEAWAY

In 1 patients with laboratory-confirmed COVID-19 from seven hospitals in China demonstrated, a two-way mixed ANOVA (treatment vs. time interaction) revealed no significant differences for patient-reported outcomes (e.g., cough, dyspnea, headache, chest pain) and oxygen saturation ( p > 0.05), except for an attenuated fatigue after HRW intervention ( p = 0.01). Since placebo drink was normalized for total magnesium amount in this trial, the effects demonstrated in the HRW group (hydrogen plus magnesium) are likely due to biological effects of hydrogen owing to the fact that no significant effects were seen in the placebo group (magnesium only). These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence inflammatory regulation.

What the Findings Mean

H2HUBB reviewed how hydrogen-rich water affected the outcomes measured in 1 patients with laboratory-confirmed COVID-19 from seven hospitals in China demonstrated. A two-way mixed ANOVA (treatment vs. time interaction) revealed no significant differences for patient-reported outcomes (e.g., cough, dyspnea, headache, chest pain) and oxygen saturation ( p > 0.05), except for an attenuated fatigue after HRW intervention ( p = 0.01). Since placebo drink was normalized for total magnesium amount in this trial, the effects demonstrated in the HRW group (hydrogen plus magnesium) are likely due to biological effects of hydrogen owing to the fact that no significant effects were seen in the placebo group (magnesium only).

What the Researchers Studied

The researchers studied 1 patients with laboratory-confirmed COVID-19 from seven hospitals in China demonstrated. The study used a randomized human clinical trial. The comparison condition was control condition or baseline measurements.

What Effects Did Molecular Hydrogen Have?

1, 2 An open-label randomized trial in 44 patients with laboratory-confirmed COVID-19 from seven hospitals in China demonstrated that 3-day hydrogen inhalation resulted in significantly more patients with improved disease severity and reduced dyspnea comparing to patients who received standard-of-care treatment. A two-way mixed ANOVA (treatment vs. time interaction) revealed no significant differences for patient-reported outcomes (e.g., cough, dyspnea, headache, chest pain) and oxygen saturation ( p > 0.05), except for an attenuated fatigue after HRW intervention ( p = 0.01). Since placebo drink was normalized for total magnesium amount in this trial, the effects demonstrated in the HRW group (hydrogen plus magnesium) are likely due to biological effects of hydrogen owing to the fact that no significant effects were seen in the placebo group (magnesium only).

Why These Findings Matter

These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence inflammatory regulation and contribute to the growing body of molecular-hydrogen research.

How Strong Is This Evidence?

This is human clinical evidence from a randomized human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.

Technical Study Details

H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 1 patients with laboratory-confirmed COVID-19 from seven hospitals in China demonstrated. The reported sample size was 44. The study used a randomized human clinical trial. The hydrogen delivery method was hydrogen-rich water.

Limitations and Safety

No separate limitations or safety findings were identified in the current-study source text available to H2HUBB.

Original Study and H2HUBB Research Context

H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.